血管内皮生长因子和基质金属蛋白酶在恶性腹水形成及诊疗中的临床意义

doi:10.3969/j.issn.1004-616x.2023.02.014

摘要/Abstract

摘要： 恶性腹水是常见的腹部恶性肿瘤的并发症，其诊断和治疗对于延缓腹部癌症患者病情发展具有非常重要的意义，目前临床上普遍认为血管内皮生长因子(VEGF)和基质金属蛋白酶(MMPs)与恶性积液的形成密切相关且在相关疾病诊断中具有参考价值及意义。因此，本文对已有的相关研究进行综述，总结恶性腹水的新型治疗方案及相关技术的应用现状，并且探讨VEGF和MMPs促进恶性腹水形成的机制及将其作为临床诊断恶性腹水标志物的可行性。

关键词: 恶性腹水, 血管内皮生长因子, 基质金属蛋白酶, 肿瘤标志物

中图分类号:

R730

余紫娟, 谈美娟, 余小红. 血管内皮生长因子和基质金属蛋白酶在恶性腹水形成及诊疗中的临床意义[J]. 癌变·畸变·突变, 2023, 35(2): 158-164.

参考文献

[1] MELINCOVICI CS, BOŞCA AB, ŞUŞMAN S, et al. Vascular endothelial growth factor (VEGF)-key factor in normal and pathological angiogenesis[J]. Revue Roumaine De Morphol Embryol, 2018, 59(2): 455-467.
[2] WANG X R, BOVE A M, SIMONE G, et al. Molecular bases of VEGFR-2-mediated physiological function and pathological role[J]. Front Cell Dev Biol, 2020, 8: 599281.
[3] 刘敏, 董卫国. 恶性腹水的形成机制及诊治研究进展[J]. 中华全科医师杂志, 2015, 14(2): 155-158.
[4] 解宇晴, 闫凤娜, 于莉华, 等. 养阴扶正解毒法治疗原发性肝癌恶性腹水临床思考[J]. 中西医结合肝病杂志, 2022, 32(10): 939-941.
[5] 张菲菲, 金世柱, 刘自帅. 恶性腹水的治疗新观点[J]. 胃肠病学和肝病学杂志, 2017, 26(4): 476-478.
[6] GOBIN E, BAGWELL K, WAGNER J, et al. A pan-cancer perspective of matrix metalloproteases (MMP) gene expression profile and their diagnostic/prognostic potential[J]. BMC Cancer, 2019, 19(1): 581.
[7] APTE R S, CHEN D S, FERRARA N. VEGF in signaling and disease: beyond discovery and development[J]. Cell, 2019, 176(6): 1248-1264.
[8] PEACH C J, MIGNONE V W, ARRUDA M A, et al. Molecular pharmacology of VEGF-A isoforms: binding and signalling at VEGFR2[J]. Int J Mol Sci, 2018, 19(4): 1264.
[9] SIVEEN K S, PRABHU K, KRISHNANKUTTY R, et al. Vascular endothelial growth factor (VEGF) signaling in tumour vascularization: potential and challenges[J]. Curr Vasc Pharmacol, 2017, 15(4): 339-351.
[10] EGUCHI R, KAWABE J I, WAKABAYASHI I. VEGFindependent angiogenic factors: beyond VEGF/VEGFR2 signaling[J]. J Vasc Res, 2022, 59(2): 78-89.
[11] 李岩, 胡冰. 恶性腹水的抗血管生成治疗进展[J]. 安徽医药, 2013, 17(4): 541-543.
[12] KOCH S, CLAESSON-WELSH L. Signal transduction by vascular endothelial growth factor receptors[J]. Cold Spring Harb Perspect Med, 2012, 2(7): a006502.
[13] 邬建飞, 字向东. VEGF家族及其受体调控雌性动物生殖活动的研究进展[J]. 中国畜牧杂志, 2022, 58(9): 69-76.
[14] ESKANDER R N, TEWARI K S. Emerging treatment options for management of malignant ascites in patients with ovarian cancer[J]. Int J Womens Health, 2012, 4: 395-404.
[15] SMOLLE E, TAUCHER V, HAYBAECK J. Malignant ascites in ovarian cancer and the role of targeted therapeutics[J]. Anticancer Res, 2014, 34(4): 1553-1561.
[16] KÜNNAPUU J, BOKHARAIE H, JELTSCH M. Proteolytic cleavages in the VEGF family: generating diversity among angiogenic VEGFs, essential for the activation of lymphangiogenic VEGFs[J]. Biology (Basel), 2021, 10(2): 167.
[17] CUI N, HU M, KHALIL R A. Biochemical and biological attributes of matrix metalloproteinases[J]. Prog Mol Biol Transl Sci, 2017, 147: 1-73.
[18] 林家钟, 王荣茂. MMPs与骨性关节炎的关系及MMPs抑制性药物的研究[J]. 福建医药杂志, 2021, 43(2): 147-150.
[19] GUO C, WANG X T, LIANG L F. LATS2-mediated YAP1 phosphorylation is involved in HCC tumorigenesis[J]. Int J Clin Exp Pathol, 2015, 8(2): 1690-1697.
[20] KOYAMA H, IWATA H, KUWABARA Y, et al. Gelatinolytic activity of matrix metalloproteinase-2 and-9 in oesophageal carcinoma；a study using in situ zymography[J]. Eur J Cancer, 2000, 36(16): 2164-2170.
[21] BELOTTI D, PAGANONI P, MANENTI L, et al. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation[J]. Cancer Res, 2003, 63(17): 5224-5229.
[22] ZHANG J, CAO Y J, LI F Y, et al. Effects of fibronectin, VEGF and angiostatin on the expression of MMPs through different signaling pathways in the JEG-3 cells[J]. Am J Reprod Immunol, 2003, 50(4): 273-285.
[23] BAGGIO C, BOSCARO C, OLIVIERO F, et al. Gender differences and pharmacological regulation of angiogenesis induced by synovial fluids in inflammatory arthritis[J]. Biomed Pharmacother, 2022, 152: 113181.
[24] 邓庆, 贺飞, 胡清桥, 等. 桑枝调控HIF-1α/VEGF/MMPs信号通路改善佐剂性关节炎大鼠骨破坏的研究[J]. 湖南中医药大学学报, 2022, 42(7): 1096-1104.
[25] CHODOBSKI A, ZINK B J, SZMYDYNGER-CHODOBSKA J. Blood-brain barrier pathophysiology in traumatic brain injury [J]. Transl Stroke Res, 2011, 2(4): 492-516.
[26] 孙晓敏, 董卫国, 余保平, 等. 检测恶性腹水中VEGF、 CD44v6和 MMP-2、MMP-9的临床意义[J]. 癌症, 2004, 23(1): 85-89.
[27] 沈忠海, 马红松. 腹水中VEGF水平检测在良恶性腹水鉴别诊断中的价值[J]. 中国卫生检验杂志, 2006, 16(5): 602-603.
[28] ZHAN N, DONG W G, WANG J. The clinical significance of vascular endothelial growth factor in malignant ascites[J]. Tumor Biol, 2016, 37(3): 3719-3725.
[29] MONAVARIAN M, ELHAW A T, TANG P W, et al. Emerging perspectives on growth factor metabolic relationships in the ovarian cancer ascites environment[J]. Semin Cancer Biol, 2022, 86: 709-719.
[30] VALENTI F, FALCONE I, UNGANIA S, et al. Precision medicine and melanoma: multi-omics approaches to monitoring the immunotherapy response[J]. Int J Mol Sci, 2021, 22(8): 3837.
[31] ZHANG J J, WU N, SHI D Y. The involvement of the mammalian target of rapamycin, protein tyrosine phosphatase 1b and dipeptidase 4 signaling pathways in cancer and diabetes: a narrative review[J]. Mini Rev Med Chem, 2021, 21(7): 803-815.
[32] 王怀碧, 江飞龙, 赖宗浪, 等. 恶性腹水的治疗现状及进展[J]. 中国中医急症, 2017, 26(12): 2162-2164.
[33] SHARIATI M, WILLAERT W, CEELEN W, et al. Aerosolization of nanotherapeutics as a newly emerging treatment regimen for peritoneal carcinomatosis[J]. Cancers (Basel), 2019, 11(7): 906.
[34] JORDAN K, LUETKENS T, GOG C, et al. Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: a multicentre doubleblind, placebo-controlled phase II study -AIO SUP-0108[J]. Eur J Cancer, 2016, 63: 127-134.
[35] ZHAO H, LI X S, CHEN D J, et al. Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial[J]. Med Oncol, 2015, 32(2): 292.
[36] SJOQUIST K M, ESPINOZA D, MILESHKIN L, et al. REZOLVE (ANZGOG-1101): a phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer[J]. Gynecol Oncol, 2021, 161(2): 374-381.
[37] 黄燕, 谢益敏, 王皓, 等. 深部热疗联合腹腔灌注贝伐珠单抗治疗恶性腹水的疗效及对患者免疫功能的影响[J]. 吉林医学, 2021, 42(1): 69-72.
[38] TAGUCHI E, NAKAMURA K, MIURA T, et al. Anti-tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model[J]. Cancer Sci, 2008, 99(3): 623-630.
[39] KINOSHITA J, FUSHIDA S, MAKINO I, et al. The use of bevacizumab in refractory peritoneal dissemination of gastric cancer with malignant ascites-two case reports[J]. Gan To Kagaku Ryoho, 2011, 38(12): 2360-2362.
[40] NUMNUM T M, ROCCONI R P, WHITWORTH J, et al. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma[J]. Gynecol Oncol, 2006, 102(3): 425-428.
[41] HAMILTON C A, MAXWELL G L, CHERNOFSKY M R, et al. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer[J]. Gynecol Oncol, 2008, 111(3): 530-532.
[42] 王营, 郭志, 倪虹. 贝伐珠单抗治疗复发性卵巢癌的应用进展[J]. 肿瘤防治研究, 2015, 42(4): 416-420.
[43] 王君萍, 汪国玉, 张梅, 等. 抗血管生成药物阿柏西普治疗转移性结直肠癌的快速卫生技术评估[J]. 中国新药杂志, 2022, 31(4): 391-396.
[44] COLOMBO N, MANGILI G, MAMMOLITI S, et al. A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites[J]. Gynecol Oncol, 2012, 125(1): 42-47.
[45] 孙辰, 田绍东, 吴寒冰, 等. 重组人血管内皮抑素不同给药方式的研究进展[J]. 生命科学仪器, 2022, 20(3): 15-22.
[46] WEI H M, QIN S K, YIN X J, et al. Endostar inhibits ascites formation and prolongs survival in mouse models of malignant ascites[J]. Oncol Lett, 2015, 9(6): 2694-2700.
[47] ZHAO W Y, CHEN D Y, CHEN J H, et al. Effects of intracavitary administration of Endostar combined with cisplatin in malignant pleural effusion and ascites[J]. Cell Biochem Biophys, 2014, 70(1): 623-628.
[48] JIANG X, GUAN W, LI M X, et al. Endostatin combined with platinum-based chemo-radiotherapy for advanced non-small cell lung cancer[J]. Cell Biochem Biophys, 2015, 71(2): 571-577.
[49] 刘卓. 西妥昔单抗联合铂类药物灌注治疗胃癌所致恶性腹水患者的临床效果观察[J]. 医学理论与实践, 2022, 35(7): 1146-1148.
[50] 于榆林. 西妥昔单抗联合铂类药物灌注治疗胃癌致恶性腹水疗效观察[J]. 现代肿瘤医学, 2021, 29(13): 2300-2304.
[51] 卓恩挺, 王连臣, 陈雪莲, 等. 西妥昔单抗联合铂类药物灌注治疗胃癌所致恶性腹水患者的疾病控制效果[J]. 疑难病杂志, 2019, 18(10): 1022-1025, 1030.
[52] 刘一秀, 张广美, 高建华. 西地尼布在卵巢癌治疗中的研究进展[J]. 医学综述, 2019, 25(15): 3035-3038, 3044.
[53] WEDGE S R, KENDREW J, HENNEQUIN L F, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer[J]. Cancer Res, 2005, 65(10): 4389-4400.
[54] 王晖, 王芳涛, 范跃祖. 抗淋巴管生成治疗结直肠癌研究进展[J]. 外科研究与新技术, 2021, 10(1): 64-67.
[55] TACCONI C, CORREALE C, GANDELLI A, et al. Vascular endothelial growth factor C disrupts the endothelial lymphatic barrier to promote colorectal cancer invasion[J]. Gastroenterology, 2015, 148(7): 1438-1451.
[56] MULDER S F, BOERS-SONDEREN M J, VAN DER HEIJDEN H F, et al. A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusion[J]. Target Oncol, 2014, 9(4): 331-338.
[57] 冯俊波, 葛圣林, 龚文辉, 等. MMP-9抑制剂巴马司他对体外循环犬肺组织中iNOS表达的影响[J]. 山东医药, 2010, 50(18): 14-16.
[58] LOW J A, JOHNSON M D, BONE E A, et al. The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice[J]. Clin Cancer Res, 1996, 2(7): 1207-1214.
[59] 龙新安, 杨大明, 牛立志, 等. 恶性腹水治疗进展[J]. 国际消化病杂志, 2013, 33(3): 155-159.
[60] PARSONS S L, WATSON S A, STEELE R J. Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites[J]. Eur J Surg Oncol, 1997, 23(6): 526-531.
[61] BEATTIE G J, SMYTH J F. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites[J]. Clin Cancer Res, 1998, 4(8): 1899-1902.
[62] WINER A, ADAMS S, MIGNATTI P. Matrix metalloproteinase inhibitors in cancer therapy: turning past failures into future successes[J]. Mol Cancer Ther, 2018, 17(6): 1147-1155.
[63] STEWARD W P, THOMAS A L. Marimastat: the clinical development of a matrix metalloproteinase inhibitor[J]. Expert Opin Investig Drugs, 2000, 9(12): 2913-2922.
[64] BECKER G, GALANDI D, BLUM H E. Malignant ascites: systematic review and guideline for treatment[J]. Eur J Cancer, 2006, 42(5): 589-597.
[65] LEVIN M, UDI Y, SOLOMONOV I, et al. Next generation matrix metalloproteinase inhibitors-Novel strategies bring new prospects[J]. Biochim Biophys Acta Mol Cell Res, 2017, 1864(11 Pt A): 1927-1939.